Cells: a possible effect
In Dalmasso’s 2008 experiments, KPV reduced chemical messages that drive inflammation—swelling and irritation—in human cells grown in a dish.
The FDA, the US Food and Drug Administration, says researchers still do not know exactly which parts of cells KPV acts on, in its review checked September 28, 2026.
Those experiments do not establish a treatment benefit for a person.
Mice: bowel findings
The Dalmasso and Kannengiesser papers from 2008 found less bowel inflammation in mice given KPV.
The bowel inflammation was caused in the lab. The results are about those animal studies, rather than people with bowel disease.
Skin: a delivery problem
Pawar’s 2017 study used donated human skin in a lab, not living patients.
When KPV was left to pass through unbroken skin on its own, too little got through for the test to detect it. That does not prove that none got through.
That finding does not show whether a particular cream works.
The question that connects the chapters
As of September 28, 2026, FDA’s review found too little evidence to judge whether KPV helps wounds heal or treats problems involving inflammation in people.
Ask whether the study shows help for your health problem in people. Ask what it could not tell the researchers, as well as what it found.